Attovia (ATTO) Director Gold Mitchell Receives 27,000-Share Award

What Happened Gold Mitchell, a director of Attovia Therapeutics, was granted a derivative award covering 27,000 shares on August 4, 2026. The Form 4 reports the acquisition price as $0.00 (derivative), indicating a compensatory grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-04; Form 4 filed: 2026-08-06 (filed within the SEC’s 2-business-day window).
• Instrument: Derivative award (27,000 shares) reported at $0.00; treated as an option grant per footnote.
• Vesting: 25% vests on August 4, 2027; remaining portion vests in equal monthly installments over the following 36 months, subject to continued service.
• Shares owned after transaction: Not specified in the information provided.
• No indication of a sale, tax withholding, 10b5-1 plan, or late filing in this report.

Context This was a compensatory derivative grant (options per the footnote) awarded to a non-employee/board director as part of compensation. Such awards are routine for corporate officers and directors and do not represent an open-market purchase or sale by the insider.